Chao T, Ho C, Cheng W, et al. 324P A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy. 2019;30(Supplement_9):mdz438. 007.

Poster: Shi, Y.; Song, Y.; Qin, Y.; Zhang, Q.; Han, X.; Hong, X.; Wang, D.; Zeng, X.; Hu, P.; Zhao, S.; Hong, K.; Ma, C.; Cheng, J.; Ting, P.; Li, K.; Jiang, W.; Liu, S.; Liu, E.; Zhang, X.; Chai, K.; Yao, D.; Luk, A., First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study. Blood 2019, 134 (suppl_1), 2878.

Oral: Xu, B.; Zhang, Q.; Sun, T.; Li, W.; Teng, Y.; Hu, X.; Bondarenko, I.; Adamchuk, H.; Zhang, L.;  Trukhin, D.; Li, B.; Shan, B.; Cheng, J.; Peng, T.; Jiang, W.; Liu, S.; Zhang, X.; Wang, Q.; Liu, E.; Luk, A., 309PDEfficacy and safety of first China-manufactured trastuzumab biosimilar HLX02 for metastatic breast cancer: A phase III trial. Annals of Oncology 2019, 30 (suppl_5), mdy242.004.